Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Subscribe To Our Newsletter & Stay Updated
